PDA

View Full Version : Celgene (Nasdaq: CELG)



Retread
11-22-2017, 12:31 PM
Looks like an opportunity but I gotta get some increase in cash flow before I can do anything. If I get in, it's a buy and hold rather than a quick fix.

SarasotaRepub
11-23-2017, 12:26 AM
Where are you looking to get in???

Retread
11-23-2017, 12:34 AM
As soon as I free up the cash. That will probably take until Monday's close.

On edit: Checking my close dates, maybe Friday.

Ole Cowboy
11-23-2017, 12:44 PM
Why Celgene Got PummeledOct.29.17 | About: Celgene Corporation (CELG) (https://seekingalpha.com/symbol/CELG)


https://static3.seekingalpha.com/images/users_profile/003/022/051/big_pic.png (https://seekingalpha.com/author/shock-exchange/articles)
Shock Exchange (https://seekingalpha.com/author/shock-exchange/articles)

Long/short equity, long only, short only, special situations
MARKETPLACE
Shocking The Street
(https://seekingalpha.com/account/research/subscribe?slug=shock-exchange&source=article_top_author_banner)



(5,429 followers)




SummaryCELG fell over 15% after Q3 earnings.
Weak guidance, slowing growth from Revlimid and questions over the pipeline weighed heavily.
CELG's near-term growth prospects do not support its 15x EBITDA multiple.
Continue to avoid CELG.



https://static.seekingalpha.com/uploads/2017/10/27/3022051-15091406540882812.jpg (https://static.seekingalpha.com/uploads/2017/10/27/3022051-15091406540882812_origin.jpg)Revlimid. Source: drugs.com
Celgene (CELG (https://seekingalpha.com/symbol/CELG)) reported Q3 earnings Thursday and it did not go well. Investors did not like what they heard and pummeled CELG, driving the stock down over 15%. The company missed on revenue (https://seekingalpha.com/news/3304446-celgene-beats-0_04-misses-revenue) by $120 million, but delivered an earnings beat. Below are three reasons why I believe the stock sold off.
Weak Guidance
Managing Wall Street's expectations is highly-important for a publicly-traded company. Analysts hate negative surprises; Celgene surprised everyone with weak full-year guidance. Management gave full-year revenue guidance of approximately $13.0 billion. That was slightly below the mid-point of $13.2 billion previously provided.
The guidance for each of the company's products was unchanged except for Otezla which is expected to achieve $1.25 billion in full-year revenue. That compares unfavorably to the previous guidance of $1.50 to $1.70 billion. Revenue from the psoriasis treatment was $308 million, up 12% Y/Y. However, Otezla is being hit (https://seekingalpha.com/article/4116886-celgene-celg-q3-2017-results-earnings-call-transcript?part=single) by a deceleration in the overall market:

In the past two years, the U.S. market for psoriasis and psoriatic arthritis grew strongly, posting TRx growth rates in the high teens versus previous years. This was fueled by new launches, including OTEZLA, which expanded the total pool of patients on treatment ...
However, year to date through September, both markets have experienced a significant slowdown in growth as a result of increasingly restrictive PBM formulary control. While OTEZLA demand continues to outpace the overall market, we are seeing lower-than-expected revenue due to market deceleration, increases in gross-to-net discounts to drive biologic step free access and inventory fluctuations.